When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer (TNBC) with an anti-drug conjugate used in monotherapy or in combination with antiPDL1.